Medtronic Total Revenue increased by 0.6% to $9.02B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.7%, from $8.29B to $9.02B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 2.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenue| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.19B | $7.99B | $7.85B | $7.76B | $8.09B | $7.37B | $7.59B | $7.73B | $8.54B | $7.70B | $7.98B | $8.09B | $8.59B | $7.92B | $8.40B | $8.29B | $8.93B | $8.58B | $8.96B | $9.02B |
| QoQ Change | — | -2.5% | -1.8% | -1.1% | +4.2% | -8.9% | +2.9% | +1.9% | +10.6% | -9.9% | +3.7% | +1.3% | +6.2% | -7.8% | +6.2% | -1.3% | +7.7% | -3.9% | +4.5% | +0.6% |
| YoY Change | — | — | — | — | -1.2% | -7.7% | -3.3% | -0.5% | +5.6% | +4.5% | +5.3% | +4.7% | +0.5% | +2.8% | +5.2% | +2.5% | +3.9% | +8.4% | +6.6% | +8.7% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3.13B | $3.01B | $3.10B | $3.04B | $3.34B | $3.29B | $3.44B | $3.46B |
| Neuroscience | $2.54B | $2.32B | $2.45B | $2.46B | $2.62B | $2.42B | $2.56B | $2.56B |
| Medical Surgical | $2.09B | $2.00B | $2.13B | $2.07B | $2.21B | $2.08B | $2.17B | $2.17B |
| Diabetes Group | $660.00M | $647.00M | $686.00M | $694.00M | $728.00M | $721.00M | $757.00M | $796.00M |
| Other operating segment | — | — | — | — | $30.00M | $33.00M | $35.00M | $32.00M |
| Total | $8.59B | $7.92B | $8.40B | $8.29B | $8.93B | $8.58B | $8.96B | $9.02B |
Other Segment is derived from annual filings.
Other was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Japan Australia New Zealand Korea Canadaand Western Europe | $2.33B | $2.16B | $2.29B | $2.63B | $2.46B | $2.37B | $2.47B | $2.68B |
| Middle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea | $1.28B | $1.36B | $1.37B | $1.44B | $1.31B | $1.44B | $1.50B | $1.57B |
| Total | $7.37B | $7.59B | $7.73B | $8.54B | $7.70B | $7.98B | $8.09B | $8.59B |
Japan Australia New Zealand Korea Canadaand Western Europe, Middle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|
| Total Other Countries Excluding Ireland | $7.89B | $8.37B | $8.26B | $8.90B | $8.55B | $8.93B | $8.98B |
| Total Other Countries Excluding United Statesand Ireland | — | — | — | $4.35B | $4.32B | $4.41B | $4.49B |
| Total | $7.92B | $8.40B | $8.29B | $8.93B | $8.58B | $8.96B | $9.02B |